Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Chong Kun Dang Pharmaceutical
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05041790CT.gov A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment | — | Unknown | — | — | — |
NCT01363648CT.gov The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cognitive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Choline Alfoscerate (this asset) | Chong Kun Dang Pharmaceutical | Approved | BB · 65 |
| Nicotine | University of Southern California | P2 | BBB |
| Oxybutynin | University of Alberta | P4 | BBB |
| Metformin | Fudan University | P4 | BB |
| Rivastigmine | VA Office of Research and Development | P4 | BB |
| Levodopa | Vanderbilt University Medical Center | P4 | BB |
| Ginkgo Biloba | Dr. Willmar Schwabe GmbH & Co. KG | P4 | BB |
| Memantine | UNC Lineberger Comprehensive Cancer Center | P3 | BB |
| Egb 761® | Ipsen | P4 | BB |
+42 more in the Cognitive Disorder cohort
Other indications for Choline Alfoscerate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Vascular Dementia | — | P4 | BB · 65 |
| Stroke Disorder | — | P4 | B · 58 |
| Alzheimer Disease | — | P4 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Choline Alfoscerate in Cognitive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/choline-alfoscerate-cognitive-disorder-34689
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →